background image

Paid Clinical Trials Surprise

Discover 1,255 paid clinical trials in Surprise, Arizona. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
Active & Responsive

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

for
Primary IgA Nephropathy
Location: 36 recruiting locations
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT05797610

Phase3, Recruiting
Active & Responsive

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

for
Atherosclerotic Cardiovascular Disease (ASCVD)
Location: 25 recruiting locations
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT06813911

Phase3, Recruiting
Active & Responsive

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

for
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Location: 89 recruiting locations
Sponsor: Cleerly, Inc.

Sex: All

Age: 55+

Code: NCT06112418

Recruiting
Active & Responsive

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

for
Ulcerative Colitis
Location: 45 recruiting locations
Sponsor: Takeda

Sex: All

Age: 18 - 65

Code: NCT06095128

Recruiting
Active & Responsive

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

for
Moderately to Severely Active Crohns Disease
Location: 76 recruiting locations
Sponsor: Hoffmann-La Roche

Sex: All

Age: 16 - 70+

Code: NCT06819878

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

for
Moderately to Severely Active Ulcerative Colitis
Location: 79 recruiting locations
Sponsor: Hoffmann-La Roche

Sex: All

Age: 16 - 70+

Code: NCT06589986

Phase3, Recruiting
Active & Responsive

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

for
Crohn's Disease
Location: 77 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 16 - 70+

Code: NCT06430801

Phase3, Recruiting
Active & Responsive

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

for
Ulcerative Colitis
Location: 50 recruiting locations
Sponsor: Gilead Sciences

Sex: All

Age: 18 - 70+

Code: NCT06290934

Phase2, Recruiting
Active & Responsive

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

for
Weight Loss
Location: 113 recruiting locations
Sponsor: Viking Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07104383

Phase3, Recruiting
Active & Responsive

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

for
NASH - Nonalcoholic Steatohepatitis,
Location: 130 recruiting locations
Sponsor: Akero Therapeutics, Inc

Sex: All

Age: 18 - 70+

Code: NCT06528314

Phase3, Recruiting